Title: Initial Experience from the INSPIRE DUCHENNE Phase I/II Study of SGT-003 Microdystrophin Gene Therapy for Duchenne ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an investigational orally ...

Bringing together eminent scientists, researchers, and industry leaders, the Longevity India Conference 2025 – Rise for ...

Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study in patients with DMD44 (oral presentation) Aravindhan Veerapandiyan, MD ...

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors ...

Boston Celtics (47-19, second in the Eastern Conference) vs. Brooklyn Nets (22-44, 12th in the Eastern Conference) New York; Saturday, 6 p.m. EDT BETMGM SPORTSBOOK LINE: Celtics -11; over/under is 214 ...

An arrowhead-shaped rock on Mars sporting features that may hint at ancient microbial activity on the Red Planet has left ...

Indiana Farm Bureau Young Farmers and Ag Professionals Conference took place in Indianapolis. The conference theme was ...

This is the Spring 2025 Membership Meeting of the Forum on Neuroscience and Nervous System Disorders. Members will receive an ...

Including two conference players of the year, these Wisconsin high-school alumni earned all-conference accolades in college.

The presentations will be available in the Publications section of REGENXBIO's website. ABOUT REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives ...

The conference provided an excellent opportunity for the wider public to connect with researchers presenting their innovative ...